131 related articles for article (PubMed ID: 34185311)
1. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.
Westphal D; Garzarolli M; Sergon M; Horak P; Hutter B; Becker JC; Wiegel M; Maczey E; Blum S; Grosche-Schlee S; Rütten A; Ugurel S; Stenzinger A; Glimm H; Aust D; Baretton G; Beissert S; Fröhling S; Redler S; Surowy H; Meier F
Br J Dermatol; 2021 Dec; 185(6):1186-1199. PubMed ID: 34185311
[TBL] [Abstract][Full Text] [Related]
2. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.
Harms PW; Hovelson DH; Cani AK; Omata K; Haller MJ; Wang ML; Arps D; Patel RM; Fullen DR; Wang M; Siddiqui J; Andea A; Tomlins SA
Hum Pathol; 2016 May; 51():25-31. PubMed ID: 27067779
[TBL] [Abstract][Full Text] [Related]
3. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
[TBL] [Abstract][Full Text] [Related]
4. Metastatic eccrine porocarcinoma: report of a case and review of the literature.
Marone U; Caracò C; Anniciello AM; Di Monta G; Chiofalo MG; Di Cecilia ML; Mozzillo N
World J Surg Oncol; 2011 Mar; 9():32. PubMed ID: 21410982
[TBL] [Abstract][Full Text] [Related]
5. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab.
Comito F; Nigro MC; Sperandi F; Melotti B; Ardizzoni A
Eur J Cancer; 2021 Mar; 146():84-86. PubMed ID: 33588148
[No Abstract] [Full Text] [Related]
7. [A case report of eccrine porocarcinoma].
Fumo G; Piras V; Pilloni L; Ferreli C; Pau M
Clin Ter; 2015; 166(4):e273-5. PubMed ID: 26378762
[TBL] [Abstract][Full Text] [Related]
8. Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas.
Bosic M; Kirchner M; Brasanac D; Leichsenring J; Lier A; Volckmar AL; Oliveira C; Buchhalter I; Stögbauer F; Zivkovic-Perisic S; Goeppert B; Schirmacher P; Penzel R; Endris V; Stenzinger A
Pathology; 2018 Apr; 50(3):327-332. PubMed ID: 29269125
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of p16 and RB protein in eccrine porocarcinoma.
Gu LH; Ichiki Y; Kitajima Y
J Cutan Pathol; 2002 Sep; 29(8):473-9. PubMed ID: 12207741
[TBL] [Abstract][Full Text] [Related]
10. Eccrine porocarcinoma with extensive cutaneous metastases.
Montes-Torres A; Pérez-Plaza A; Llamas-Velasco M; Gordillo C; De Argila D; García-García C; Fraga J; Marín A; Ballesteros AI; Daudén E
Int J Dermatol; 2016 Mar; 55(3):e156-60. PubMed ID: 26566927
[TBL] [Abstract][Full Text] [Related]
11. Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.
Denisova E; Westphal D; Surowy HM; Meier F; Hutter B; Reifenberger J; Rütten A; Schulz A; Sergon M; Ziemer M; Brors B; Betz RC; Redler S
Cancer Gene Ther; 2022 Jun; 29(6):697-708. PubMed ID: 34045664
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
13. A Rare Case of Eccrine Porocarcinoma of the Eyelid.
Chua PY; Cornish KS; Stenhouse G; Barras CW
Semin Ophthalmol; 2015; 30(5-6):443-5. PubMed ID: 24576261
[TBL] [Abstract][Full Text] [Related]
14. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
Marks JL; Gong Y; Chitale D; Golas B; McLellan MD; Kasai Y; Ding L; Mardis ER; Wilson RK; Solit D; Levine R; Michel K; Thomas RK; Rusch VW; Ladanyi M; Pao W
Cancer Res; 2008 Jul; 68(14):5524-8. PubMed ID: 18632602
[TBL] [Abstract][Full Text] [Related]
15. Mohs micrographic surgery for eccrine porocarcinoma: an update and review of the literature.
Song SS; Wu Lee W; Hamman MS; Jiang SI
Dermatol Surg; 2015 Mar; 41(3):301-6. PubMed ID: 25742554
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
17. EGFR inhibitor AG1478 blocks the formation of 3D structures mainly through ERK signaling pathway in Matrigel-induced 3D reconstruction of eccrine sweat gland-like structures.
Chen L; Du L; Zhang L; Xie S; Zhang X; Li H
J Mol Histol; 2020 Apr; 51(2):191-197. PubMed ID: 32219645
[TBL] [Abstract][Full Text] [Related]
18. Eccrine porocarcinoma: a report of 2 cases and review of the literature.
Nguyen A; Nguyen AV
Cutis; 2014 Jan; 93(1):43-6. PubMed ID: 24505584
[TBL] [Abstract][Full Text] [Related]
19. Eccrine poroma and porocarcinoma on the same unusual location: report on two cases.
Ma H; Liao M; Qiu S; Lu R; Lu C
An Bras Dermatol; 2015; 90(3 Suppl 1):69-72. PubMed ID: 26312678
[TBL] [Abstract][Full Text] [Related]
20. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis.
Qiao L; Studer E; Leach K; McKinstry R; Gupta S; Decker R; Kukreja R; Valerie K; Nagarkatti P; El Deiry W; Molkentin J; Schmidt-Ullrich R; Fisher PB; Grant S; Hylemon PB; Dent P
Mol Biol Cell; 2001 Sep; 12(9):2629-45. PubMed ID: 11553704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
